Bisphosphonate‑related Osteonecrosis of the Jaw (BRONJ)
Overview
Bisphosphonate‑related osteonecrosis of the jaw (BRONJ) is a serious, but relatively uncommon, condition in which the jawbone (maxilla or mandible) is exposed and fails to heal, leading to necrotic (dead) bone tissue. It occurs in patients who have been exposed to nitrogen‑containing bisphosphonates—powerful drugs prescribed to treat osteoporosis, multiple myeloma, and bone metastases from solid tumors.
- Who it affects: Primarily adults over 50 years old who receive high‑dose intravenous (IV) bisphosphonates for cancer, but it can also occur in oral bisphosphonate users for osteoporosis.
- Prevalence: The incidence varies widely:
- IV bisphosphonates (e.g., zoledronic acid): 1%–14% in cancer patients (higher with longer exposure)【1】.
- Oral bisphosphonates (e.g., alendronate): <0.1%–0.2% in osteoporosis patients【2】.
- Why the jaw? The jawbones have high remodeling rates and are often exposed to dental trauma (extractions, implants), which can trigger necrosis when bone turnover is suppressed by bisphosphonates.
Symptoms
Symptoms may be subtle at first and progress over weeks to months. Not every patient experiences every sign.
- Exposed bone: A visible area of necrotic bone in the gum, often painless at onset.
- Pain or tenderness: Ranges from mild discomfort to severe throbbing, especially when chewing.
- Swelling: Soft‑tissue edema around the lesion; may become inflamed or purulent.
- Red or purulent discharge: May smell foul; indicates secondary infection.
- Loose teeth or tooth loss: Necrotic bone undermines tooth stability.
- Sensation changes: Numbness, tingling, or burning in the jaw, palate, or chin (cranial nerve V involvement).
- Difficulty opening the mouth (trismus): Due to muscle spasm or infection.
- Fistula formation: An abnormal channel from bone to oral mucosa that continuously drains.
- Jaw fracture: In advanced cases, the weakened bone may fracture spontaneously or after minor trauma.
Causes and Risk Factors
Underlying Mechanism
Bisphosphonates bind to hydroxyapatite in bone and inhibit osteoclast‑mediated resorption. Over‑suppression reduces the bone’s ability to remodel and repair micro‑injuries, leading to accumulation of micro‑fractures and eventual necrosis when an additional insult (e.g., dental extraction) occurs.
Key Risk Factors
- Drug‑related: High‑potency IV bisphosphonates (zoledronic acid, pamidronate) > oral agents. Cumulative dose > 2 years markedly raises risk.
- Cancer diagnosis: Multiple myeloma, breast, prostate, or lung cancer with bone metastases.
- Concomitant therapies: Corticosteroids, anti‑angiogenic agents (bevacizumab, sunitinib), heavy smoking, and chemotherapy.
- Dental procedures: Extractions, implant placement, periodontal surgery, or even ill‑fitting dentures that cause chronic trauma.
- Pre‑existing oral disease: Periodontitis, osteomyelitis, or poor oral hygiene.
- Systemic conditions: Diabetes mellitus, renal insufficiency, and immunosuppression.
- Genetics: Emerging data suggest polymorphisms in genes regulating bone turnover may predispose certain individuals, though evidence is still limited.
Diagnosis
BRONJ is a clinical diagnosis supported by imaging and laboratory work‑up. The American Association of Oral and Maxillofacial Surgeons (AAOMS) criteria require:
- Current or previous exposure to a bisphosphonate.
- Exposed necrotic bone in the maxilla or mandible that persists for >8 weeks.
- No history of radiation therapy to the jaws.
Clinical Examination
- Inspection for exposed bone, fistulas, or ulceration.
- Palpation for tenderness, crepitus, or fluctuance.
- Assessment of oral function (mouth opening, phonation, chewing).
Imaging Studies
- Panoramic radiograph (OPG): Provides an overview; may show radiolucent zones or sclerosis.
- Cone‑beam CT (CBCT) or conventional CT: Gold standard for evaluating extent, cortical perforation, and proximity to vital structures.
- MRI: Useful when soft‑tissue infection or osteomyelitis is suspected.
Laboratory Tests
- Complete blood count (CBC) and C‑reactive protein (CRP) to gauge infection.
- Serum electrolytes, renal function, and calcium/phosphate if underlying metabolic disease is a concern.
- Microbiological swabs of discharge for culture‑guided antibiotic therapy (optional).
Treatment Options
Management is multidisciplinary—dentists, oral surgeons, oncologists, and primary care physicians work together. The main goals are to control infection, relieve pain, and halt disease progression.
Conservative (Stage 0–1)
- Oral hygiene optimization: Antimicrobial mouth rinses (chlorhexidine 0.12% BID).
- Systemic antibiotics: Amoxicillin‑clavulanate or clindamycin for 7–14 days if infection is present.
- Pain control: Acetaminophen, NSAIDs (if renal function permits), or low‑dose opioids.
- Bisphosphonate drug holiday: Consider a temporary discontinuation (typically 2–3 months) in consultation with the prescribing oncologist; evidence for benefit is mixed but may reduce further bone exposure.
Surgical Intervention (Stages 2–3)
- Debridement & sequestrectomy: Removal of necrotic bone while preserving healthy tissue.
- Resection & reconstruction: In extensive disease, segmental resection followed by free‑flap reconstruction may be necessary.
- Adjunctive therapies:
- Platelet‑rich plasma (PRP) or platelet‑rich fibrin (PRF) to promote healing.
- Low‑level laser therapy (LLLT) for pain reduction and tissue regeneration (limited evidence).
- Medication adjuncts:
- Teriparatide (recombinant PTH 1‑34) has shown benefit in selected patients with osteoporosis‑related BRONJ (off‑label use, discuss with endocrinology).
- Pentoxifylline + vitamin E (“PENTO”) protocol for radiation‑associated osteonecrosis may have benefit, but evidence is anecdotal.
Follow‑up Care
- Regular dental check‑ups every 3–6 months.
- Serial imaging to confirm disease stability.
- Re‑evaluation of bisphosphonate therapy; alternative agents (e.g., denosumab) have their own osteonecrosis risk and should be considered case‑by‑case.
Living with Bisphosphonate‑related Osteonecrosis of the Jaw
Daily Management Tips
- Gentle oral hygiene: Use a soft‑bristled toothbrush, non‑abrasive toothpaste, and avoid vigorous flossing around exposed bone.
- Moisturize: Saliva substitutes or water‑based mouth sprays can reduce dryness that impedes healing.
- Dietary modifications: Soft, non‑acidic foods; avoid nuts, hard crackers, or chewing gum that may traumatize the jaw.
- Smoking cessation: Smoking impairs vascular supply and delays bone healing.
- Alcohol moderation: Excessive alcohol interferes with bone metabolism and medication efficacy.
- Regular dental visits: Promptly address any new sore, loose tooth, or swelling.
- Medication review: Keep an up‑to‑date list of all drugs (including over‑the‑counter) and share it with every provider.
- Stress management: Chronic pain can affect mental health; consider counseling, mindfulness, or support groups.
Prevention
Prevention focuses on minimizing trauma to the jaw and careful use of bisphosphonates.
- Dental evaluation before starting bisphosphonates: Complete oral examination, treat active infections, and perform necessary extractions at least 2 weeks prior to the first dose.
- Maintain impeccable oral hygiene: Brush twice daily, floss gently, and use antimicrobial rinses if recommended.
- Avoid invasive dental procedures while on high‑dose therapy: If unavoidable, coordinate with the prescribing physician for a possible drug holiday and prophylactic antibiotics.
- Use the lowest effective bisphosphonate dose and duration: Follow oncology or osteoporosis guidelines; reassess need for continued therapy annually.
- Educate patients: Provide written information about early signs of BRONJ and when to call a dentist.
Complications
If untreated or poorly managed, BRONJ can lead to serious sequelae:
- Chronic infection: Osteomyelitis that may spread to adjacent structures (sinus, ear, or cranial cavity).
- Pathologic fracture: Weakening of the mandible or maxilla can result in fracture after minimal trauma.
- Malnutrition: Painful chewing leads to weight loss and nutritional deficiencies.
- Quality‑of‑life impact: Persistent pain, speech difficulty, and facial disfigurement can cause depression and social withdrawal.
- Secondary malignancy masking: Persistent ulceration may obscure early signs of oral cancer; regular evaluation is essential.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Severe, uncontrolled facial or jaw pain unresponsive to prescribed analgesics.
- Rapid swelling of the face, neck, or mouth that is warm to the touch.
- Fever ≥ 100.4°F (38°C) with chills, indicating possible sepsis.
- Difficulty breathing, swallowing, or speaking (risk of airway obstruction).
- Sudden loose teeth that fall out spontaneously.
- Visible pus or foul odor from the jaw that suddenly worsens.
- Signs of jaw fracture—visible deformity, audible “crack,” or inability to open the mouth.
These symptoms may signal a spreading infection or an impending fracture, both of which require immediate medical attention.
References
- American Association of Oral and Maxillofacial Surgeons. “AAOMS Position Paper on Medication‑Related Osteonecrosis of the Jaw.” J Oral Maxillofac Surg. 2022.
- Mayo Clinic. “Bisphosphonate‑related osteonecrosis of the jaw.” Updated 2023. https://www.mayoclinic.org
- National Cancer Institute. “Bone‑Targeted Agents and Osteonecrosis of the Jaw.” 2021.
- Cleveland Clinic. “Osteonecrosis of the Jaw: Causes, Symptoms, Treatment.” 2023.
- World Health Organization. “Guidelines for the Use of Anti‑resorptive Agents in Cancer Patients.” 2022.